Issuer/Instrument | Industry/ Rating |
% to Net Assets |
---|---|---|
Equity & Equity Related |
||
Reliance Industries Ltd. | Petroleum Products | 12.58 |
HDFC Bank Ltd. | Banks | 9.57 |
ICICI Bank Ltd. | Banks | 9.20 |
Infosys Ltd. | IT - Software | 7.93 |
HDFC Ltd. | Finance | 6.37 |
Tata Consultancy Services Ltd. | IT - Software | 4.72 |
ITC Ltd. | Diversified FMCG | 4.47 |
Kotak Mahindra Bank Ltd. | Banks | 3.99 |
Hindustan Unilever Ltd. | Diversified FMCG | 3.69 |
Larsen And Toubro Ltd. | Construction | 3.42 |
Axis Bank Ltd. | Banks | 3.11 |
State Bank Of India | Banks | 3.05 |
Bajaj Finance Ltd. | Finance | 3.00 |
Bharti Airtel Ltd | Telecom - Services | 3.00 |
Asian Paints Ltd. | Consumer Durables | 2.31 |
Mahindra & Mahindra Ltd. | Automobiles | 1.86 |
Maruti Suzuki India Limited | Automobiles | 1.80 |
Titan Company Ltd. | Consumer Durables | 1.67 |
Bajaj Finserv Ltd. | Finance | 1.60 |
Sun Pharmaceuticals Industries Ltd. | Pharmaceuticals & Biotechnology | 1.57 |
HCL Technologies Ltd. | IT - Software | 1.51 |
Tata Steel Ltd. | Ferrous Metals | 1.23 |
IndusInd Bank Ltd. | Banks | 1.18 |
National Thermal Power Corporation Limited | Power | 1.16 |
Power Grid Corporation Of India Ltd. | Power | 1.11 |
Ultratech Cement Ltd. | Cement & Cement Products | 1.11 |
Nestle India Ltd. | Food Products | 1.04 |
Tech Mahindra Ltd. | IT - Software | 0.98 |
Wipro Ltd. | IT - Software | 0.90 |
Dr Reddys Laboratories Ltd. | Pharmaceuticals & Biotechnology | 0.81 |
Equity & Equity Related - Total | 99.94 | |
Net Current Assets/(Liabilities) | 0.06 | |
Grand Total | 100.00 |
Regular Plan
Fund Manager | Mr. Devender Singhal & Mr. Satish Dondapati* |
Benchmark | S&P BSE SENSEX TRI |
Allotment date | June 6, 2008 |
AAUM | Rs21.58 crs |
AUM | Rs21.05 crs |
Folio count | 2,028 |
Portfolio Turnover | 14.03% |
Tracking Error: | 0.04% |
Through Exchange: 1 Unit ,
Through AMC: 10000 Units,
Ideal Investment Horizon: 5 years and
above
Entry Load: Nil. (applicable for all plans)
Exit Load:
Nil (applicable for all plans)
Regular: 0.28%
Fund
Benchmark
* Investors should consult their financial advisers if in doubt about whether the product is suitable for them.